Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 44Urinary Bladder Neoplasms 42Testicular Neoplasms 30Carcinoma, Transitional Cell 30Ovarian Neoplasms 28Testicular Germ Cell Tumor 16Carcinoma, Non-Small-Cell Lung 14Melanoma 11Kidney Neoplasms 11Carcinoma, Renal Cell 11Breast Neoplasms 11Wilms Tumor 10Urethral Neoplasms 10Teratoma 10Sarcoma 10Pancreatic Neoplasms 10Central Nervous System Neoplasms 10Colorectal Neoplasms 9Neuroectodermal Tumors, Primitive, Peripheral 8Neoplasm Metastasis 8Stomach Neoplasms 7Ovarian Germ Cell Cancer 7Neoplasms 7Seminoma 6Osteosarcoma 6Neuroblastoma 6Lung Neoplasms 6Head and Neck Neoplasms 6Ureteral Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5

Interventions

sipuleucel-T 1Docetaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hormone-Refractory Prostate Cancer × Carboplatin × Genitourinary × Clear all
NCT00675545 2012-04-02

A Phase II Study of Docetaxel Plus Carboplatin in Chemonaive Hormone-Refractory Prostate Cancer (HRPC) Patients

National University Hospital, Singapore

Phase 2 Completed
2 enrolled
Genitourinary

Hormone-Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡